CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade Estadual Paulista (UNESP). Campus de Araraquara. Faculdade de Ciências Farmacêuticas (FCFAR) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Natalia de Moraes, Ph.D., is an assistant professor at the Center for Pharmacometrics & Systems Pharmacology at University of Florida College of Pharmacy. She received her B.S. in Pharmaceutical Sciences from the University of Sao Paulo, Brazil in 2006. Dr. De Moraes received her Ph.D. from the University of Sao Paulo (Brazil) under the supervision of Dr. Vera Lanchote in 2011. Her research activities includes an internship as a graduate student at the Center for Applied Pharmacokinetic Research (CAPKR), in the University of Manchester. Dr. De Moraes was an Assistant Professor at Sao Paulo State University (UNESP) for 9 years. She was part of the advisory board in the graduate programs of Pharmaceutical Sciences at Sao Paulo State University and Toxicology at the University of Sao Paulo. In 2020-2021, she served as a consultant to set health-based exposure limits for Cristalia Produtos Químico-Farmacêuticos Ltda (Brazil) and for Instituto BioChimico Industria Farmaceutica (Brazil). In 2019 and 2020, her research group was awarded with best poster and best oral presentation in the V Congress of the Brazilian Association of Pharmaceutical Sciences and in the 12th International Congress of Pharmaceutical Sciences (CIFARP), respectively, due to their work on precision dosing and pharmacometrics. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Clinical pharmacology research has focused for many years on phase I and phase II metabolism to predict the elimination of xenobiotics. However, in the last decade, clinical pharmacology recognized that the kinetic disposition of drugs is also highly dependent on the expression and activity of transporting proteins. The organic anion transporting polypeptide 1A2 (OATP1A2) expressed in the…
Modeling and simulation (M&S) in physiologically-based pharmacokinetics (PBPK) studies have recently been recognized by American and European regulatory agencies for decision-making in drug development. This approach has been used to explore and quantitatively predict drug-drug interactions in virtual populations. In this study, modeling and simulation in PBPK will be used to predict the …
The organic cation transporter 2 (OCT2), expressed at the basolateral membrane of proximal tubule of the kidneys, plays an important role in the elimination of several clinically available drugs. Gabapentin (GBP), anticonvulsant used to treat neuropathic pain, is partially eliminated by renal active secretion via OCT2. The experimental diabetes mellitus (EDM) induced by streptozotocin (ST…
(Only some records are available in English at this moment)
Paediatric doses are often derived from adult dosages based on bodyweight. However, growing up is related not only to an increased bodyweight but changes in intrinsic activity and expression of drug-metabolizing enzymes, receptors and transporters. Linearly extrapolating the adult dose to children based on bodyweight may result in intoxication, therapeutic failure or even fatalities. Ther…